JPMorgan Chase & Co. Has $316,000 Stake in Genmab A/S (NASDAQ:GMAB)

JPMorgan Chase & Co. reduced its position in Genmab A/S (NASDAQ:GMAB) by 53.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,943 shares of the company’s stock after selling 14,567 shares during the period. JPMorgan Chase & Co.’s holdings in Genmab A/S were worth $316,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Point72 Asset Management L.P. acquired a new position in Genmab A/S during the second quarter worth $457,000. Sanctuary Advisors LLC acquired a new stake in shares of Genmab A/S in the 2nd quarter worth about $1,354,000. Ritholtz Wealth Management acquired a new stake in shares of Genmab A/S in the 3rd quarter worth about $314,000. Creative Planning lifted its position in Genmab A/S by 136.3% in the 3rd quarter. Creative Planning now owns 47,422 shares of the company’s stock valued at $1,156,000 after acquiring an additional 27,353 shares in the last quarter. Finally, Bleakley Financial Group LLC boosted its stake in Genmab A/S by 7.7% during the 3rd quarter. Bleakley Financial Group LLC now owns 30,732 shares of the company’s stock valued at $749,000 after purchasing an additional 2,196 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $19.81 on Friday. The company has a market capitalization of $13.11 billion, a PE ratio of 19.23, a price-to-earnings-growth ratio of 0.57 and a beta of 0.97. Genmab A/S has a 52-week low of $19.02 and a 52-week high of $31.88. The company has a 50-day simple moving average of $21.06 and a 200 day simple moving average of $23.79.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period in the prior year, the company earned $0.47 EPS. As a group, analysts forecast that Genmab A/S will post 1.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on GMAB shares. Redburn Atlantic started coverage on Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.